Compared to the CGRP-antagonist trials, patients had tried a significantly greater number of preventatives and had higher HIT6 scores at baseline.
CGRP-antagonists reduced headache frequency to the same degree as reported in clinical trials.
There were no significant differences in demographic data that predicted response to therapy in the episodic and chronic migraine patient groups.
While there was a subset of patients who were super-responders and a subset who are non-responders, it does not appear that number of failed preventives, age, or gender are predictive of response to therapy.
Side effects, particularly constipation in the chronic migraine group, were more common than reported in clinical trials.